Berenberg initiated coverage of Harmony Biosciences with a Buy rating and $59 price target, implying 67% upside. The analyst views Harmony as a “de-risked story” that is currently trading near the low end of its 52-week range. The firm recommends buying the shares ahead of the Phase 3 INTUNE data readout.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HRMY:
- Harmony Biosciences receives FDA orphan drug designation for pitolisant
- Harmony Biosciences patent news ‘clear positive,’ says Mizuho
- Harmony Biosciences comments on ‘favorable’ decision by USPTO on WAKIX
- Biotech Alert: Searches spiking for these stocks today
- Zynerba downgraded to Hold from Buy at Canaccord